Pharmacyte Biotech Inc (OTCMKTS:PMCB) highlighted major goals that need to be met in order to begin Phase 2b study for pancreatic cancer treatment. This study will examine the safety and efficacy of designed pancreatic cancer treatment. The therapy is a well-planned combination of microcapsules comprising genetically modified live cells and ifosfamide dosage.
Pharmacyte revealed that in order to treat the disease these encapsulated live cells will be positioned in proximity to cancerous tumor. It will announce a number of major objectives in the coming period that will assist company in its first clinical trial. Many of these objectives must be fulfilled before an IND is filed with the drug regulatory bodies.
Nutra Pharma Corp. (OTCMKTS:NPHC) highlighted that U.S. FDA granted the Orphan Drug designation to its RPI-78M drug candidate for cure of Multiple Sclerosis in kids. The drug was first obtained from cobra venom extract and is a opponent of the nicotinic acetylcholine receptor. This potential drug has an exceptionally low toxicity and can be used in a variety of applications.
Scientific publications have validated that modified and native neurotoxins are known to safeguard nerve cells from pre-mature cell death. Furthermore, the expectations are that RPI-78M may be of use in neuromuscular disorders. The know-how is covered by patents detailing the application and use of RPI-78M in autoimmune and viral diseases treatment.
Growblox Sciences Inc (OTCMKTS:GBLX) stated that Sandra Tiffany, an ex- Nevada Senator is appointed as the GM of GB Sciences Nevada LLC. Tiffany in her previous role held numerous leadership profiles and designed game changing legislation. She had been an important part of legislation when state of Nevada voters accepted the “Medical Marijuana Act.”
Tiffany has been on non-profit advisory boards and she has been recognized in her community. She possesses deep experience in entrepreneurial business as she established her first company at the age of thirty.
